Cover Image
市場調查報告書

癡呆症:開發平台分析

Dementia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 245960
出版日期 內容資訊 英文 243 Pages
訂單完成後即時交付
價格
Back to Top
癡呆症:開發平台分析 Dementia - Pipeline Review, H2 2017
出版日期: 2017年08月16日 內容資訊: 英文 243 Pages
簡介

所謂癡呆症是指思考力·記憶力·推理力等日常生活機能相關的重要精神機能受損狀態。主要的症狀有記憶力衰退和妄想、興奮、人格變化、調整·運動能力、障礙等。致病的危險因子有年齡和抽煙、肥胖症、高血壓、發炎、心血管疾病等。

本報告提供全球各國治療癡呆症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

癡呆症概要

治療藥的開發

  • 癡呆症開發中產品:概要
  • 癡呆症開發中產品:比較分析

各企業開發中的癡呆症治療藥

大學/研究機關研究中的癡呆症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

癡呆症治療藥:開發中的產品的一覽(各企業)

癡呆症治療藥:研究中的產品的一覽(大學/研究機關別)

癡呆症開發治療藥的企業

  • Adamas Pharmaceuticals, Inc.
  • AgeneBio Inc.
  • Alector LLC
  • AlzProtect SAS
  • Amarantus Bioscience Holdings, Inc.
  • Axon Neuroscience SE
  • Axovant Sciences Ltd.
  • BioArctic Neuroscience AB
  • Biogen, Inc.
  • Biotie Therapies Corp.
  • Boehringer Ingelheim GmbH
  • Chase Pharmaceuticals Corporation
  • Daewoong Pharmaceutical Co., Ltd.
  • Eisai
  • FORUM Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • Heptares Therapeutics Limited
  • Hyundai Pharmaceutical Co., Ltd.
  • Ildong Pharmaceutical Co., Ltd.
  • Immungenetics AG
  • ImStar Therapeutics Inc.
  • Integrative Research Laboratories Sweden AB
  • Intellect Neurosciences, Inc.
  • Intra-Cellular Therapies, Inc.
  • MediPost Co., Ltd.
  • Neuraltus Pharmaceuticals, Inc.
  • Neurimmune Holding AG
  • Neurodyn Inc.
  • Oryzon Genomics S.A.
  • Ovid Therapeutics Inc.
  • P2D Bioscience
  • Pacific Northwest Biotechnology, LLC
  • Pivot Pharmaceuticals Inc
  • Sinil Pharmaceutical Co., Ltd
  • Stelic Institute & Co., Inc.
  • 大日本住友製藥
  • Sylentis S.A.U.
  • TauRx Therapeutics Ltd.
  • WhanIn Pharmaceutical Co., Ltd.

癡呆症:治療藥的評估

  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AADvac-1
  • Antisense Oligonucleotides to Inhibit microRNA for Neurology
  • Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia
  • AVCRI-104P3
  • AZP-2006
  • BAN-0805
  • BI-409306
  • CB-2233
  • CB-8411
  • choline alfoscerate SR
  • CPC-201
  • CPC-252
  • D-217
  • dehydroevodiamine hydrochloride
  • Drugs for Dementia
  • Drugs to Agonize c-MET for Dementia
  • Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment
  • DWJ-1365
  • E-2609
  • eltoprazine
  • encenicline hydrochloride
  • FRM-0334
  • GIBH-130
  • Gln-1062
  • GTC-6000
  • gugulipid
  • HOB-075
  • HTL-18318
  • IRL-752
  • ITI-007
  • KR-12
  • levetiracetam
  • LH-026
  • LUAF-20513
  • MM-201
  • Monoclonal Antibodies for Dementia and Alzheimer's Disease
  • Monoclonal Antibodies to Inhibit Tau for CNS Disorders
  • NAT
  • nelotanserin
  • Neurostem
  • NI-205
  • NI-308
  • NNC-269100
  • NP-001
  • OG-635
  • ORY-2001
  • OV-201
  • P-003
  • PD-2015
  • PD-2016
  • PD-2024
  • PD-2244
  • PD-61W3
  • Peptide to Inhibit BACE for Cerebropathy and Dementia
  • PST-900
  • RVT-101
  • salicylamine
  • SIN-1502
  • Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders
  • Small Molecule to Activate LPL for CNS and Metabolic Disorders
  • Small Molecule to Inhibit Glycogene 5 for Dementia
  • Small Molecules for Frontotemporal Dementia
  • Small Molecules for Ophthalmology and CNS Disorders
  • Small Molecules to Agonize HGFR for CNS Disorders
  • Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia
  • Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease
  • SND-14
  • SYN-120
  • Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders
  • TAK-070
  • TauC-3
  • TPI-287
  • TRx-0237
  • TTT-3002
  • WIB-1001C
  • zonisamide

癡呆症治療藥:開發中產品的最新趨勢

癡呆症治療藥:開發暫停的產品

癡呆症治療藥:開發中止的產品

癡呆症相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9614IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H2 2017, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 11, 19, 1, 39, 10 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 11 and 3 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Dementia - Overview
  • Dementia - Therapeutics Development
  • Dementia - Therapeutics Assessment
  • Dementia - Companies Involved in Therapeutics Development
  • Dementia - Drug Profiles
  • Dementia - Dormant Projects
  • Dementia - Discontinued Products
  • Dementia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Dementia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Dementia - Pipeline by Accera Inc, H2 2017
  • Dementia - Pipeline by Acorda Therapeutics Inc, H2 2017
  • Dementia - Pipeline by Actinogen Medical Ltd, H2 2017
  • Dementia - Pipeline by Adamas Pharmaceuticals Inc, H2 2017
  • Dementia - Pipeline by AgeneBio Inc, H2 2017
  • Dementia - Pipeline by Alector LLC, H2 2017
  • Dementia - Pipeline by Allergan Plc, H2 2017
  • Dementia - Pipeline by AlzProtect SAS, H2 2017
  • Dementia - Pipeline by Anavex Life Sciences Corp, H2 2017
  • Dementia - Pipeline by Asceneuron SA, H2 2017
  • Dementia - Pipeline by Axon Neuroscience SE, H2 2017
  • Dementia - Pipeline by Axovant Sciences Ltd, H2 2017
  • Dementia - Pipeline by BioArctic AB, H2 2017
  • Dementia - Pipeline by Biogen Inc, H2 2017
  • Dementia - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Dementia - Pipeline by Cortice Biosciences Inc, H2 2017
  • Dementia - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
  • Dementia - Pipeline by Echo Pharmaceuticals BV, H2 2017
  • Dementia - Pipeline by Eisai Co Ltd, H2 2017
  • Dementia - Pipeline by Eli Lilly and Company, H2 2017
  • Dementia - Pipeline by H. Lundbeck A/S, H2 2017
  • Dementia - Pipeline by Heptares Therapeutics Ltd, H2 2017
  • Dementia - Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017
  • Dementia - Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017
  • Dementia - Pipeline by Immungenetics AG, H2 2017
  • Dementia - Pipeline by Intellect Neurosciences Inc, H2 2017
  • Dementia - Pipeline by Intra-Cellular Therapies Inc, H2 2017
  • Dementia - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
  • Dementia - Pipeline by Johnson & Johnson, H2 2017
  • Dementia - Pipeline by M3 Biotechnology Inc, H2 2017
  • Dementia - Pipeline by MediPost Co Ltd, H2 2017
  • Dementia - Pipeline by Neuraltus Pharmaceuticals Inc, H2 2017
  • Dementia - Pipeline by Neurimmune Holding AG, H2 2017
  • Dementia - Pipeline by Neuropore Therapies Inc, H2 2017
  • Dementia - Pipeline by Oryzon Genomics SA, H2 2017
  • Dementia - Pipeline by P2D Bioscience, H2 2017
  • Dementia - Pipeline by Pacific Northwest Biotechnology LLC, H2 2017
  • Dementia - Pipeline by Pharmasum Therapeutics AS, H2 2017
  • Dementia - Pipeline by Prana Biotechnology Ltd, H2 2017
  • Dementia - Pipeline by Sage Therapeutics Inc, H2 2017
  • Dementia - Pipeline by Sinil Pharmaceutical Co Ltd, H2 2017
  • Dementia - Pipeline by Stemedica Cell Technologies Inc, H2 2017
  • Dementia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
  • Dementia - Pipeline by Suven Life Sciences Ltd, H2 2017
  • Dementia - Pipeline by TauRx Therapeutics Ltd, H2 2017
  • Dementia - Pipeline by Theranexus SAS, H2 2017
  • Dementia - Pipeline by Vicore Pharma AB, H2 2017
  • Dementia - Pipeline by Voyager Therapeutics Inc, H2 2017
  • Dementia - Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2017
  • Dementia - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017
  • Dementia - Dormant Projects, H2 2017
  • Dementia - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Dementia - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Dementia - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Dementia - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Dementia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top